Stock comparison
Haemonetics
Bio-Techne
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
TECH
Bio-Techne
Market cap
$7.55B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | TECH | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 55C | HAE |
| Benjamin Graham | 85A | 89A | TECH |
| Philip Fisher | 60C | 50C | HAE |
| Peter Lynch | 54C | 24F | HAE |
| Joel Greenblatt | 31F | 50D | TECH |
| Charlie Munger | 54D | 45D | HAE |
| Terry Smith | 55D | 44D | HAE |
Side-by-side metrics
| Metric | HAE | TECH |
|---|---|---|
| Market cap | $2.98B | $7.55B |
| P/E (TTM) | 24.8x | 61.6x |
| EV/EBIT | 14.1x | 67.1x |
| ROIC (TTM) | 8.37% | 4.75% |
| Gross margin | 55.74% | 64.96% |
| Net margin | 7.29% | 9.05% |
| Revenue CAGR 5y | 7.65% | 6.98% |
| EPS CAGR 5y | 24.62% | -15.23% |
| Debt / Equity | 1.5x | 0.1x |
| Dividend yield | 0.0% | 0.74% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs -15.23%+162%
- EV/EBIT14.1xvs 67.1x+79%
- P/E (TTM)24.8xvs 61.6x+60%
- ROIC (TTM)8.37%vs 4.75%+43%
TECH leads on
- Dividend yield0.74%vs 0.0%+100%
- Debt / Equity0.1xvs 1.5x+91%
- Market cap$7.55Bvs $2.98B+61%
- Net margin9.05%vs 7.29%+19%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.